G. Mayor

Results of the phase I open label clinical trial SAKK 06/14 assessing safety of intravesical instillation of VPM1002BC, a recombinant mycobacterium Bacillus Calmette Guérin (BCG), in patients with non-muscle invasive bladder cancer and previous failure of conventional BCG therapy

F. Spertini, A. Wicki, G. Wirth, 2020, Oncoimmunology.

Attenuation of experimental tobramycin nephrotoxicity by ticarcillin

W. Bennett, D. Gilbert, P. Kohnen, 1985, Antimicrobial Agents and Chemotherapy.

Results of the phase-I open-label clinical trial SAKK 06/14 assessing safety of intravesical instillation of the recombinant BCG VPM1002BC in patients with non-muscle invasive bladder cancer and previous failure to conventional BCG therapy

F. Spertini, A. Wicki, G. Wirth, 2018 .